CTOs on the Move

Sequella

www.sequella.com

 
Sequella is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sequella.com
  • 9610 Medical Center Dr Ste 200
    Rockville, MD USA 20850
  • Phone: 301.762.7776

Executives

Name Title Contact Details

Similar Companies

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.

PharmScript

At PharmScript, we are healthcare professionals first. Together, we believe in the power of helping our clients deliver true patient-centered care.

ROSE LifeScience

Cultivation. Commercialization. Logistics. Yes, we`re here to make your life and work happier, and it starts with remarkable cannabis. It continues with business-ready services which help simplify the regulated world. From our proud home in Huntingdon, our family of marketers, growers and industry leaders at ROSE LifeScience are making cannabis thrive in Québec — for our customers, partners, communities and (especially) for you. Happiness is indeed our business. More importantly, it`s the reason why we do business.

Sofwave

Sofwave is the latest technology to reduce wrinkles and fine lines in a single 45 min non-invasive treatment with no post-care needed

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.